Cargando…

Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model

The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Qauli, Ali Ikhsanul, Yoo, Yedam, Marcellinus, Aroli, Lim, Ki Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/
https://www.ncbi.nlm.nih.gov/pubmed/36290499
http://dx.doi.org/10.3390/bioengineering9100531
_version_ 1784816387229745152
author Qauli, Ali Ikhsanul
Yoo, Yedam
Marcellinus, Aroli
Lim, Ki Moo
author_facet Qauli, Ali Ikhsanul
Yoo, Yedam
Marcellinus, Aroli
Lim, Ki Moo
author_sort Qauli, Ali Ikhsanul
collection PubMed
description The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have only looked at the effects of mexiletine on action potential duration (APD) or QT interval reduction. We further investigated mexiletine’s effects on cardiac cells through simulations of single-cell (behavior of alternant occurrence) and 3D (with and without mexiletine). We discovered that mexiletine could shorten the cell’s APD and change the alternant’s occurrence to a shorter basic cycle length (BCL) between 350 and 420 ms. The alternant also appeared at a normal heart rate under the A1656D mutation. Furthermore, the 3D ventricle simulations revealed that mexiletine could reduce the likelihood of a greater spiral wave breakup in the A1656D mutant condition by minimizing the appearance of rotors. In conclusion, we found that mexiletine could provide extra safety features during therapy for LQT3 patients because it can change the alternant occurrence from a normal to a faster heart rate, and it reduces the chance of a spiral wave breakup. Therefore, these findings emphasize the promising efficacy of mexiletine in treating LQT3 patients under the A1656D mutation.
format Online
Article
Text
id pubmed-9598628
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95986282022-10-27 Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model Qauli, Ali Ikhsanul Yoo, Yedam Marcellinus, Aroli Lim, Ki Moo Bioengineering (Basel) Brief Report The SCN5A mutations have been long associated with long QT variant 3 (LQT3). Recent experimental and computation studies have reported that mexiletine effectively treats LQT3 patients associated with the A1656D mutation. However, they have primarily focused on cellular level evaluations and have only looked at the effects of mexiletine on action potential duration (APD) or QT interval reduction. We further investigated mexiletine’s effects on cardiac cells through simulations of single-cell (behavior of alternant occurrence) and 3D (with and without mexiletine). We discovered that mexiletine could shorten the cell’s APD and change the alternant’s occurrence to a shorter basic cycle length (BCL) between 350 and 420 ms. The alternant also appeared at a normal heart rate under the A1656D mutation. Furthermore, the 3D ventricle simulations revealed that mexiletine could reduce the likelihood of a greater spiral wave breakup in the A1656D mutant condition by minimizing the appearance of rotors. In conclusion, we found that mexiletine could provide extra safety features during therapy for LQT3 patients because it can change the alternant occurrence from a normal to a faster heart rate, and it reduces the chance of a spiral wave breakup. Therefore, these findings emphasize the promising efficacy of mexiletine in treating LQT3 patients under the A1656D mutation. MDPI 2022-10-07 /pmc/articles/PMC9598628/ /pubmed/36290499 http://dx.doi.org/10.3390/bioengineering9100531 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Qauli, Ali Ikhsanul
Yoo, Yedam
Marcellinus, Aroli
Lim, Ki Moo
Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title_full Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title_fullStr Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title_full_unstemmed Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title_short Verification of the Efficacy of Mexiletine Treatment for the A1656D Mutation on Downgrading Reentrant Tachycardia Using a 3D Cardiac Electrophysiological Model
title_sort verification of the efficacy of mexiletine treatment for the a1656d mutation on downgrading reentrant tachycardia using a 3d cardiac electrophysiological model
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598628/
https://www.ncbi.nlm.nih.gov/pubmed/36290499
http://dx.doi.org/10.3390/bioengineering9100531
work_keys_str_mv AT qaulialiikhsanul verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel
AT yooyedam verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel
AT marcellinusaroli verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel
AT limkimoo verificationoftheefficacyofmexiletinetreatmentforthea1656dmutationondowngradingreentranttachycardiausinga3dcardiacelectrophysiologicalmodel